39 results about "Control subjects" patented technology

The invention discloses a safety control method and system for an emerging control main body, and belongs to the technical field of power system active control, and the method comprises the steps: carrying out the bidirectional data interaction through a master station AGC and a field station AGC, and carrying out the bidirectional data interaction based on a bidirectional data interaction result and a cooperative anti-error parameter; whether the emerging control main body is in a controllable state or not is judged in real time through collaborative security locking logic; if the control main body is in the controllable state, active measurement data of the emerging control main body are obtained, and jump detection and multi-source checking are carried out on the active measurement data; after verification is passed, a pre-control instruction is generated based on the control strategy, and reasonability verification and control effect simulation verification are carried out; and after the control effect simulation verification is passed, the pre-control instruction is taken as a final control instruction to be issued to the emerging control main body for execution. The method can greatly improve the safety control capability of AGC on an emerging control main body, guarantees the frequency operation safety of a power grid, and improves the safe and reliable power supply capability of the power grid.

Disclosed herein are methods of treating ALS in a subject by administering a therapeutically effective amount of a composition comprising EVs, e.g., derived from neural cells, e.g., neural progenitor cells, to the subject. The EVs can be administered distally or peripherally to the CNS, such that the EVs cross the blood brain barrier and exert their therapeutic function in the CNS. The methods can reduce inflammation (e.g., NLRP3 inflammatory pathway signaling), reduce disease activity or progression, and / or improve motor or neurological performance, signs or symptoms associated with ALS, or survival in the ALS subject as compared to a control ALS subject. The methods of inhibiting necroptosis in a cell by contacting the cell with a therapeutically effective amount of a composition comprising EVs are also provided.

The invention relates to the technical field of curtain wall safety management, in particular to a smart curtain wall management device based on SAAS multiple tenants and a management system thereof.The smart curtain wall management device comprises a management main body used for collecting and sending data, a guiding device used for guiding a recording device, a limiting device used for supporting the recording main body and a clamping main body used for installing the recording main body; the front side of the management main body is fixedly connected with an operation screen, the rear side of the management main body is fixedly connected with a control main body, and the management main body, the operation screen, a placement groove, a guide device, a limiting device, a recording device, a clamping main body, the control main body, a mounting plate, an antenna main body and a plug are arranged; when the curtain wall is damaged, the damaged curtain wall can be registered through the operation screen, or the damaged curtain wall is shot through the recording device, and then the shot image is sent to a current management server through the management main body and the control main body via the Internet to be registered, so that the curtain wall can be conveniently and timely maintained.

A method for treating perinatal mood disorders in women diagnosed with or at risk for the perinatal mood disorders. The method includes administering a digital therapeutic to the subject, the digital therapeutic configured to provide cognitive behavioral therapy content to the subject to treat the perinatal mood disorders, wherein the perinatal mood disorders are treated, thereby causing the subject to exhibit an improvement upon completion of the cognitive behavioral therapy content relative to a control subject that was not administered the digital therapeutic. In some embodiments, the digital therapeutic can be administered in conjunction with a pharmacotherapeutic.

The utility model relates to the technical field of filling equipment, in particular to a clamping mechanism of a filling machine, which comprises a control main body, clamping arms which are relatively opened and closed are arranged in the control main body, and a driving structure for driving the clamping arms to switch between a clamping position and a releasing position is arranged in the control main body; the control main body and the mounting main body are matched and relatively slide in the vertical direction, a filling head is further arranged on the control main body, and the filling head synchronously descends or ascends along with the mounting main body. By controlling the opening and closing actions of the clamping arms, the opening of the container is held, fixed or released, so that more accurate and reliable filling operation of the filling head can be realized, the filling reliability and the production efficiency are improved, and meanwhile, pollution or leakage of products in the filling process can be avoided.

Disclosed herein are methods of treating ALS in a subject by administering to the subject a therapeutically effective amount of a composition comprising, for example, EV derived from nerve cells, such as neural progenitor cells. The EVs may be administered distally or peripherally to the CNS such that these EVs cross the blood-brain barrier and exert their therapeutic function in the CNS. The methods may reduce inflammation (e.g., NLRP3 inflammatory pathway signaling), reduce disease activity or progression, and / or improve motor or neurological performance, signs or symptoms associated with ALS, or survival in an ALS subject as compared to a control ALS subject. Also provided are methods of inhibiting necroptosis in a cell by contacting the cell with a therapeutically effective amount of a composition comprising EV.

The invention provides a game interaction control method and device, equipment, a storage medium and a program product, and the method comprises the steps: responding to a first operation, controlling to separate a second object from a first object, and controlling the second object to move in a game scene; and in response to the condition that the second object and the third object meet the preset position, controlling to provide the target resource for the first object, in response to the condition that the target resource meets the preset condition, the use permission of a target skill is configured for the first object, and the target skill comprises a first skill which consumes the target resource during use so as to enable the first object to move towards the second object and / or a second skill which consumes the target resource during use so as to enable the second object to move towards the first object. Spatial linkage is established between the first object and the second object based on a bidirectional displacement skill of target resource unlocking, complex tactical maneuver can be realized without frequently switching a control main body, and the tactical dimension and the strategy depth of a game are expanded.

The specification describes an antibody capture process comprising (i) obtaining a biological sample comprising antibodies, (ii) contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex. The process may further comprise (iii) directly or indirectly assessing the level of the pIgR-dIgA complex or the level of a complex between pIgR-dIgA and an antigen of interest. There is also an antibody capture process for determining gut wall integrity in a test subject, wherein the level or ratio of SIgA to dIgA is compared to a corresponding level or ratio from a control subject. The specification provides kits embodying the process and recombinant pIgR when used for, or for use, in capturing or detecting dIgA and / or IgM.

In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.

Methods are disclosed for treating a subject with an autoimmune disease. These methods include selecting a subject with the autoimmune disease that has i) an increase in ABC, DN1 cells, DN2 cells, DN3 cells and / or plasmablasts in a blood sample obtained from the subject as compared to control subjects, and / or ii) an increase of T-bet, CXCR3, CD326, VISTA, Ly6H, CD317 and / or IFNγ expressing lymphocytes as compared to a control; iii) elevated serum concentration of IL-12 and / or IFNγ as compared to a control, and / or iv) elevated anti-RNA or anti-SM antibodies as compared to a control, and administering to the subject an effective amount of IL-12 antagonist. Methods are disclosed for selecting a subject with an autoimmune disease that can be treated with an IL-12 antagonist. In some aspects, the autoimmune disease is systemic lupus erythematosus (SLE) or Sjogren's syndrome. Compositions including a therapeutically effective of an IL-12 antagonist for use in these methods are also disclosed.

Provided herein is a method of training a machine-learning model to detect cardiomyopathy in a subject, the method including providing a training dataset, the training dataset including cardiac diagnostic data from a group of subjects; identifying, in the training dataset, cardiac diagnostic data from positive subjects with cardiomyopathy and cardiac diagnostic data from control subject without cardiomyopathy; and training the machine-learning model with the training dataset to discriminate between the cardiac diagnostic data from positive subjects and the cardiac diagnostic data from control subjects. Also provided herein are a method of detecting cardiomyopathy in a subject using the machine-learning model trained according to the methods disclosed herein, an apparatus for implementing the method of detection cardiomyopathy, and a computer readable storage medium storing computer-executable instructions for performing the method.

A system for detecting alcoholism using EEG signal processing, comprising: an EEG signal acquisition module configured to acquire digitized EEG signals from a plurality of electrodes placed on the scalp of a subject according to a 10-20 electrode placement system; a signal preprocessing module operationally connected to the EEG signal acquisition module and configured to preprocess the acquired digitized EEG signals, the preprocessed EEG signals being stored in a database containing signals from both alcohol-dependent and control subjects;a computing unit comprising at least one processor with dedicated memory, wherein the processor is configured to receive the preprocessed digitized EEG signals and perform a multi-resolution signal decomposition based on the discrete cosine harmonic wavelet packet transform (DCHWPT) to generate transformed signal representations corresponding to different frequency subbands; a feature extraction module connected to the computing unit and configured to extract a variety of features from the transformed signal representations; a feature selection module configured to perform a statistical test to reduce the dimensionality of the extracted features and retain only relevant features;a classification module configured to categorize EEG signals into an alcoholic or control category based on the retained relevant features; and an output module connected to the classification module, the output module comprising a user interface configured to display the classified results to the user.

Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects. Also provided herein are methods of treating brain cancer in a subject, comprising measuring an expression level of at least one mRNA biomarker selected from SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1, HOXD13, TGFβR3, UBA7, SFRP4, or any combination thereof, in a tumor sample from a subject and administering IL-12; an immunogenic composition hTERT, WT-1, and PSMA; and an anti-PD-1 antibody to said subject if the expression level of SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1 and HOXD13 is decreased or if the expression level of TGFβR3, UBA7, SFRP4 is increased.

The present invention relates to a method of diagnosing cancer in a subject comprising detecting in the DNA of said subject at least one hypermethylated CpG island associated with said cancer, wherein an elevation in the level of methylation in said CpG island of said subject, relative to the level of methylation in said CpG island of a control subject, is indicative of said CpG island being hypermethylated.

Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

The present invention provides a method of diagnosing endometriosis and / or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and / or protein in the sample; c) detecting a level of expression of a BCL6 gene and / or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and / or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and / or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and / or protein greater than the level of expression of the SIRT1 gene and / or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and / or protein that is greater than the level of expression of the BCL6 gene and / or protein of the control subject or population of control subjects.

The application provides a neural feedback training device based on near-infrared data and a storage medium. The neural feedback training device comprises a processor configured to acquire first blood oxygen concentration data of a relevant brain area of a trainee in a training phase and second blood oxygen concentration data of the relevant brain area in a rest phase; in the training phase, a group of regularly arranged objects is presented on a display interface relative to the movement of a controlled subject, and the objects that touch the controlled subject are accommodated or deformed by the stretchable controlled subject; the stretch state of the controlled subject is associatedly presented based on the first blood oxygen concentration data; in the rest phase, the stretchable controlled subject is presented on the display interface and the regularly arranged object group is not presented, and the stretch state of the controlled subject is associatedly presented based on the second blood oxygen concentration data. In this way, the trainee can concentrate on the training task and improve the effect of rehabilitation treatment.

Disclosed is an application of sBCMA as a biomarker in cerebrospinal fluid in diagnosis and monitoring of antibody-mediated central nervous system autoimmune diseases. Taking NMOSD as an example, the level of sBCMA in cerebrospinal fluid of NMOSD patients is significantly higher than that of control subjects matched for age and gender, and there is a positive correlation between the level of sBCMA in cerebrospinal fluid and a nerve injury-related index NFL, a blood-cerebrospinal fluid barrier breakdown-related index QAlb, or a neuroinflammation-related index sTREM2 in cerebrospinal fluid of NMOSD patients. This indicates that the level of sBCMA in cerebrospinal fluid can be used as a biomarker for the diagnosis of antibody-mediated central nervous system autoimmune diseases such as NMOSD and the evaluation of the severity of nerve injuries, the degree of damage to blood-cerebrospinal fluid barrier, and the level of neuroinflammation in patients.

The invention relates to the technical field of industrial control systems, and discloses a carrier attitude adaptive compensation system in a complex motion environment, which comprises a distributed adaptive control module, a multi-dimensional state synchronization module and an axial control module, and is characterized in that the axial control module obtains a transmission time delay state, and when the transmission time delay exceeds a threshold interval, the multi-dimensional state synchronization module carries out adaptive compensation on a carrier attitude; a speed residual error sequence is extracted, the zero-crossing frequency of the speed residual error sequence is counted, an attenuation factor is determined according to the zero-crossing frequency so as to reduce the cross-axis compensation amount amplitude, an axial control module converts deviation energy generated by link congestion into a virtual uncertainty boundary parameter and injects the virtual uncertainty boundary parameter into a stability constraint criterion, and dynamic adjustment of the updating step length is completed. According to the method, the uncertainty of a communication link is quantified into robust gain reserve of a control system, the excitation phenomenon caused by high-frequency disturbance is effectively suppressed, and negative definite convergence of a controlled subject attitude control law is guaranteed.

Methods using measuring alpha activity in the brain are provided for the detection and / or diagnosis of a mild traumatic brain injury in a subject. The methods comprise measuring an alpha activity in the brain of a subject, wherein an increase in the alpha activity in the brain of the subject compared to control subjects without a brain injury or to a baseline of the subject is indicative of the subject having the mild traumatic brain injury. The alpha activity may be measured when the subject is in a resting state. The methods may further comprise administering a therapy such as a pain or headache medication to the subject with a mild traumatic brain injury.

Schizophrenia (SCZ) is the most debilitating of the Serious Mental Illnesses, a group of disorders affecting 4.8% of Arizona adults. The lack of a biologically based test makes diagnosing SCZ difficult, particularly for the 40% of Arizonans in areas with inadequate mental health care. Even under ideal circumstances, it can take months to years to accurately diagnose SCZ and identify an effective medication regimen. There is a critical need to identify biological markers to rapidly diagnose SCZ, which will lead to faster symptom resolution and improved patient outcomes. Methods described herein capitalize on the long-recognized association between SCZ risk and immune system dysfunction by stimulating peripheral blood immune cells with immunogenic agents to gain insight into disrupted pathways of gene expression in the brain. The immune stimulation of peripheral blood cells produces a unique pattern of gene expression, which will differ between SCZ and healthy control subjects.

A method for diagnosing Alzheimer's Disease or determining susceptibility to Alzheimer's Disease includes steps of obtaining a blood sample from a target subject and extracting cell-free (cf) DNA from the blood sample as extracted cf DNA. The degree of methylation in one or a plurality of Alzheimer indicator genes in the extracted cf DNA is identified. Each Alzheimer indicator gene identified is an indicator of the presence of or risk of developing Alzheimer's Disease where the plurality of Alzheimer indicators genes have been identified by a machine learning technique or by logistic regression. The target subject is identified as being at risk for Alzheimer's Disease if the amount of methylation of one or more Alzheimer's indicator genes differs from the amount of methylation established in control subjects not having Alzheimer's Disease to a statistically significant degree.

The invention provides a silk winder with a tension adjusting device, and belongs to the technical field of tension adjustment. Comprising a control body and a base, the base is fixedly connected to the top of the control body, the L-shaped air pipe is fixedly connected to the end, close to the control body, of the top of the base, and the tension mechanism comprises two sets of half-hole connecting air pipes. The upward thrust can reduce the influence of the gravity on the silk yarn, so that the resultant force on the silk yarn in the vertical direction is closer to zero, the tension fluctuation of the silk yarn caused by the gravity factor is further effectively reduced, the silk yarn is kept in a relatively stable tension state in the whole reeling process, and the reeling quality of the silk yarn is improved. Therefore, the phenomenon that the tension of the silk threads between the comb-shaped tensioner fixed group and the silk guide device is unstable can be reduced in the long-time silk winding process, the situation that the silk threads cannot be evenly and tightly arranged on an H-shaped silk tube is avoided, the probability that the inner layer is loose, the outer layer is too tight or the silk threads are locally bulged is reduced, and the silk winding quality is improved.

The application discloses application of sBCMA in cerebrospinal fluid as a biomarker in diagnosis and disease monitoring of antibody-mediated central nervous system autoimmune diseases. Taking NMOSD as an example, the level of sBCMA in cerebrospinal fluid of NMOSD patients is significantly higher than that of age and gender matched control subjects, and the level of sBCMA in cerebrospinal fluid is positively correlated with NFL, QAlb and sTREM2, which are related indexes of nerve injury, blood-cerebrospinal fluid barrier damage and nerve inflammation in cerebrospinal fluid of NMOSD patients, which shows that the level of sBCMA in cerebrospinal fluid can be used as a biomarker for diagnosis of NMOSD and other antibody-mediated central nervous system autoimmune diseases, and can also be used for evaluation of the severity of nerve injury, the degree of blood-cerebrospinal fluid barrier damage and the level of nerve inflammation of patients with central nervous system autoimmune diseases.

The invention discloses a water supply network leakage cooperative control method and system, and the method comprises the steps: carrying out the unified organization of the multi-source operation information of the operation state of an execution mechanism based on the topological structure of a water supply network, and constructing an action condition leakage confidence field which can be recursively updated along with the control action and monitoring response; under the constraint conditions of the water supply service level and the operation safety, the action condition leakage confidence field is used as a control state to represent a self-adaptive determined control mode, and the control action intensity of the active identification stage is constrained through excitation budget parameters; dividing a pipe network into a plurality of cooperative control units and setting control subjects, wherein each control subject generates candidate control actions based on local observed quantity and confidence summary information exchanged by adjacent units; and projecting the candidate control action to a safe and feasible action set through an action mapping operator, and executing consistency coordination correction at a partition boundary or a shared execution mechanism to obtain a final control action, and issuing and executing the final control action.

The present invention discloses the application of sTREM2 in the diagnosis or clinical symptom assessment of the acute attack phase of neuromyelitis optica spectrum disorder (NMOSD). The level of sTREM2 in the cerebrospinal fluid of NMOSD patients during the acute attack phase is significantly higher than that in the clinical remission phase of NMOSD patients and healthy control subjects. Moreover, there is a positive correlation between the level of sTREM2 in the cerebrospinal fluid and the degree of demyelination and neurological deficit in the acute attack phase of NMOSD. This indicates that the level of sTREM2 in the cerebrospinal fluid of NMOSD patients can serve as a biomarker for the acute attack phase of NMOSD patients and can reflect the severity of myelin loss and neurological deficit in NMOSD patients. At the same time, the present invention also determines that there is a positive correlation between sTREM2 in the cerebrospinal fluid and microglial activation and neuroinflammation in the acute attack phase of NMOSD. Therefore, as a biomarker, sTREM2 can provide a powerful auxiliary means for the early warning, clinical symptom assessment, and neuroinflammatory damage of NMOSD patients.

OF THE INVENTION USE OF VDAC AND LAMP1 AS MARKERS FOR DETECTING POCKED RED BLOOD CELLS Counting vacuole-containing RBC (pocked-RBC) is a robust marker of defective spleen function but requires the expertise of fewer and fewer specialized laboratory technicians. Now the inventors have identified VDAC and LAMP1 as markers for detecting pocked red blood cells. In particular, after performing a proteomic analysis, the inventors confirmed the presence of these proteins in splenectomized subjects by western blot. RBC of splectomized and control subjects were then marked with antibodies LAMP1 or VDAC and passed to cytometry. RBC from control subjects did not have labelling but there were RBC marked for splenectomized subjects. RBC labelling were then observed in DIC and pocked cells with vacuoles marked were quantified. No marked vacuole was observed in control subjects whereas between 4 and 33% of pocked cells had at least one vacuole marked with antibodies LAMP1 or VDAC. Since, these proteins are not found in control subjects, it is therefore possible to use this markers for detecting pocked RBCs and thus splenectomized subjects.

An electrolysis apparatus operation system includes an electrolysis apparatus, a control unit, a target state-of-health value input unit, and a control parameter calculating unit. The electrolysis apparatus has a plurality of electrolytic stacks in which a plurality of electrolytic cells that produce hydrogen by electrolyzing water are stacked. The control unit controls a controlled subject based on a control parameter that affects state-of-health of the controlled subject. The target state-of-health value input unit allows a system user to input a target state-of-health value that is a target value for state-of-health. The control parameter calculating unit calculates a control parameter of the controlled subject based on the target state-of-health value. The controlled subject is the electrolysis apparatus.